RxDoctor Payments Data

Iqbal Ahmed, MD

Internal Medicine · Okeechobee, FLNPI 1962424549

Payments from drug & device makers

$531in general payments, 2019–2025

Across 30 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$90
  • Amgen$79
  • AstraZeneca$68
  • Pfizer$68
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • Novo Nordisk$47
  • plus $118 from 3 others

What the payments were for

  • Food & beverage$51697%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$531 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$165,547
Medicare patients
261
Services billed
1,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$201,068
MounjaroTirzepatide125$143,856
XareltoRivaroxaban134$97,658
JanuviaSitagliptin Phosphate43$56,715
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$48,247
XifaxanRifaximin11$38,492
JardianceEmpagliflozin31$32,997
TrulicityDulaglutide17$21,213
MyrbetriqMirabegron13$15,679
SymbicortBudesonide/Formoterol Fumarate45$14,548
Tresiba Flextouch U-100Insulin Degludec15$11,430
Breo ElliptaFluticasone/Vilanterol19$10,492
Advair HfaFluticasone Propion/Salmeterol11$8,334
Mesalamine12$7,568
Albuterol Sulfate HfaAlbuterol Sulfate176$7,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$68$203,833213 claims
Johnson & JohnsonXarelto$90$97,658134 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$43$62,38084 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$62$38,49211 claims
AstraZenecaSymbicort$68$14,54845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Okeechobee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →